CymaBay Therapeutics, Inc.
CBAY
Rank in Stocks
#5774
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical... CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Share Price
$32.48
Last synced: 2024-03-25
Market Cap
$2.24B
Change (1 day)
0.00%
Change (1 year)
-0.01%
Country
US
Trade CymaBay Therapeutics, Inc. (CBAY)
Category
Healthcare
Stock price history for CymaBay Therapeutics, Inc. (CBAY)
Highest end of day price: $32.38 on 2024-03-01
Lowest end of day price: $11.69 on 2018-01-01
Lowest end of day price: $11.69 on 2018-01-01
Stock price history of CymaBay Therapeutics, Inc. from 2018 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2024 | 49.45% |
| 2023 | 354.32% |
| 2022 | 40.76% |
| 2021 | -44.18% |
| 2019 | -15.64% |
| 2018 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $525.12 | 23.14% |
US
|
|
| $237.61 | 784.95% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $887.75 | 9.04% |
NL
|
|
| $289.96 | 1.88% |
BE
|
